Choreo LLC Buys Shares of 6,904 Moderna, Inc. (NASDAQ:MRNA)

Choreo LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 6,904 shares of the company’s stock, valued at approximately $802,000.

Other large investors also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC increased its stake in shares of Moderna by 7.5% in the fourth quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock worth $266,000 after purchasing an additional 187 shares in the last quarter. Ontario Teachers Pension Plan Board bought a new position in Moderna in the 4th quarter worth approximately $1,358,000. Hobbs Group Advisors LLC purchased a new position in Moderna in the 4th quarter valued at approximately $664,000. Illinois Municipal Retirement Fund raised its holdings in Moderna by 22.1% during the 1st quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company’s stock valued at $5,519,000 after acquiring an additional 9,360 shares during the period. Finally, Swedbank AB bought a new stake in Moderna during the 1st quarter valued at $3,315,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Barclays reduced their price target on Moderna from $168.00 to $155.00 and set an “overweight” rating for the company in a research report on Friday, August 2nd. The Goldman Sachs Group decreased their price target on Moderna from $204.00 to $178.00 and set a “buy” rating on the stock in a research report on Friday, August 2nd. TD Cowen cut their price objective on shares of Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research report on Friday. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and reduced their price objective for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. downgraded shares of Moderna from a “neutral” rating to an “underweight” rating and cut their price target for the company from $88.00 to $70.00 in a report on Friday. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $108.53.

Moderna Price Performance

MRNA opened at $68.28 on Friday. The stock has a 50-day moving average price of $95.06 and a 200-day moving average price of $111.68. The stock has a market capitalization of $26.17 billion, a P/E ratio of -4.36 and a beta of 1.67. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. During the same period last year, the firm posted ($3.62) earnings per share. The business’s revenue was down 29.9% compared to the same quarter last year. Equities analysts predict that Moderna, Inc. will post -9.52 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Moderna news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the completion of the transaction, the president now owns 1,457,089 shares in the company, valued at approximately $201,311,416.24. The disclosure for this sale can be found here. Insiders have sold a total of 108,158 shares of company stock worth $13,239,712 in the last 90 days. 15.70% of the stock is owned by company insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.